-
, acute kidney injury transition to renal fibrosis); as well as high-throughput screening strategies to identify small molecular compounds that might serve as novel therapeutic agents in disease using cell
-
, acute kidney injury transition to renal fibrosis); as well as high-throughput screening strategies to identify small molecular compounds that might serve as novel therapeutic agents in disease using cell
-
, acute kidney injury transition to renal fibrosis); as well as high-throughput screening strategies to identify small molecular compounds that might serve as novel therapeutic agents in disease using cell
-
well as high-throughput screening strategies to identify small molecular compounds that might serve as novel therapeutic agents in disease using cell culture, kidney organoid, and mouse models. Successful